LMRI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Lumexa Imaging Holdings, Inc. Common Stock · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 10.41 USD
-4.8% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -7.3% below the Trend Line and sits at 30.5% of its 52-week range. The latest completed week returned -4.8%, after a -16.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 9d.

Setup score 25 out of 100
Latest Close 10.41 USD 31 Jul 2026
1W Return -4.8% latest completed week
4W Return -16.3% short-term follow-through
12W Return -0.1% quarterly tape
Trend Breadth 0.0% 0 of 34 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.46% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.8% Latest completed week; four-week move -16.3%. Indicator stack 0/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.46% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 52/100 67 relevant articles in the latest sentiment read. Event risk 9d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -7.3% below the Trend Line and sits at 30.5% of its 52-week range. The latest completed week returned -4.8%, after a -16.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2612-week average 0.11

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.26Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -16.3% over four weeks, -0.1% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.8%
4W-16.3%
12W-0.1%
26W-15.0%
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.55Latest activity-pressure read.
Pressure change33.0%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength10/100Blend of value, momentum, and quality. Underlying universe rank 91; rank 1 is best.
Value25/100Relative valuation strength. Underlying universe rank 76; rank 1 is best.
Quality23/100Profitability and accounting quality. Underlying universe rank 78; rank 1 is best.
Momentum37/100Medium-term price momentum. Underlying universe rank 64; rank 1 is best.
Growth67/100Revenue and earnings growth. Underlying universe rank 34; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework43/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.0x
Market value relative to trailing revenue.
EV / EBITDA
13.9x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
11.5%
Gross profit retained from each unit of revenue.
Operating margin
8.4%
Operating profit retained from revenue.
Free-cash-flow margin
4.0%
Free cash flow generated from revenue.
Return on invested capital
4.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
7.8%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-40.8%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-41.5%
Net share repurchases relative to market value.
Shareholder yield
-41.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
6.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 67 relevant articles.

11 positive · 54 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings9dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-46.5%Distance below the 52-week high.
13-week volatility13.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+33.0%Week of 13 Feb.
Worst week-34.2%Week of 27 Mar.
Latest week-4.8%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains3
Flat weeks0
Modest losses8
Sharp losses6
Recent vol13.7%13-week weekly-return volatility.
Base vol13.5%52-week weekly-return volatility.
Up/down split13/20Count of positive and negative weeks in the 52-week window.
Average skew10.8% / -8.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape26/100

Trend, activity pressure, participation, and risk combine to a 26/100 tape read.

 Indicator analysis24/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.26; No reversal markers Next-Week ExpectancyNegative 42.46%

Next-week expectancy is negative with a 42.46% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors22/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 95; Small Cap Core rank 79 SVQF43/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 416.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 67 relevant articles.

Top Lumexa Imaging (LMRI) Competitors 2026 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings9d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202610.41 USD-4.8%11.24 USD12.03 USD0.55-1.7MOff
24 Jul 202610.93 USD-1.9%11.47 USD12.08 USD0.61-1.7MOff
17 Jul 202611.14 USD-7.2%11.71 USD12.11 USD0.64-2.3MOff
10 Jul 202612.00 USD-3.5%11.93 USD12.14 USD0.55-2.0MOff
3 Jul 202612.43 USD2.7%12.15 USD12.15 USD0.41-3.4MOff
26 Jun 202612.10 USD28.6%-12.14 USD0.24-4.2MOff
19 Jun 20269.41 USD-2.4%-12.14 USD--3.7MOff
12 Jun 20269.64 USD13.4%-12.24 USD--5.1MOff
5 Jun 20268.50 USD9.3%-12.34 USD--3.0MOff
29 May 20267.78 USD-2.7%-12.49 USD--2.3MOff
22 May 20268.00 USD13.8%-12.69 USD--7.5MOff
15 May 20267.03 USD-32.5%-12.89 USD--9.3MOff
8 May 202610.42 USD4.2%-13.16 USD--2.2MOff
1 May 202610.00 USD4.2%-13.29 USD--2.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.